Super User

Super User

Tuesday, 03 May 2022 13:52

Head of the Lab

Name: Fabrizio Bianchi

University and Training: MSc in Biological Sciences (University of Milan), PhD in molecular and biological sciences (University of Milan).

Work experience: He worked as postdoctoral fellow at the FIRC Institute for Molecular Oncology (IFOM), Milan (Italy), and then at the Program of Molecular Medicine of the European Institute of Oncology (Milan). He was a visiting scientist at the Nuffield Department of Clinical and Laboratory Sciences at University of Oxford. Since 2016 he has been the Head of the Cancer Biomarkers Unit at the Research Hospital (IRCCS) Casa Sollievo della Sofferenza. He has several years of research experience in the fields of cancer genomics and biomarkers development, particularly in the field of circulating miRNAs, cancer gene expression profile and computational biology. He has contributed to the identification of a serum circulating miRNA-signature for lung cancer early detection, which was patented and transferred to a SME (Gensignia Ltd). He is inventor of international patents regarding diagnostic and prognostic tools for lung cancer screening (US8747867B2; US20150057159A1; US20160068913A1). He is an active member of the American Association for Cancer Research (AACR), the European Association for Cancer Research (EACR), the International Association for the Study of Lung Cancer (IASLC), the Italian Society for Cancer Research (AIRC), and the Italian Society of Cancerology (SIC), where he holds the positions of secretary and member of the steering committee.

Scientific area of interest: Transcriptome of solid cancer and cancer biomarkers

Collaborations: Istituto Europeo di Oncologia (IEO, Milan, Italy), IRCCS San Raffaele (Milan), University of Milan, Istituto di Nanotecnologia – CNR in Lecce (Italy), Roma Tre University (Rome, Italy), University of Navarra (Spain), Fred Hutchinson Cancer Research Center (USA).

Tuesday, 03 May 2022 13:52

Staff

PostDoc:

Dott. Tommaso Colangelo (t.colangelo@operapadrepio.it)
Dott. Roberto Cuttano (r.cuttano@operapadrepio.it)
Dott.ssa Valentina Melocchi (v.melocchi@operapadrepio.it)

PhD students:

Dott. Elisa Dama (e.dama@operapadrepio.it)
Dott. Francesco Mazzarelli (f.mazzarelli@operapadrepio.it)

Fellow:

Dott.ssa Kuku Afanga (k.afanga@operapadrepio.it)

Tecnician:

Dott.ssa Patricia Kiptiu (p.kiptiu@operapadrepio.it)

Undergraduate student:

Ms. Rosa Maria Perrone

Tuesday, 03 May 2022 13:52

Publications

Total number of publications from 2011: n. 42

List of publications (Most relevant):

  1. Colangelo T, Carbone A, Mazzarelli F, Cuttano R, Dama E, Nittoli T, Albanesi J, Barisciano G, Forte N, Palumbo O, Graziano P, di Masi A, Colantuoni V, Sabatino L, Bianchi F*, Mazzoccoli G*. Loss of circadian gene Timeless induces EMT and tumor progression in colorectal cancer via Zeb1-dependent mechanism. Cell Death Differ. 2022 Jan 15. doi: 10.1038/s41418-022-00935-y. Epub ahead of print. PMID: 35034102. * co-last authorship
  2. Dama E, Colangelo T, Fina E, Cremonesi M, Kallikourdis M, Veronesi G, Bianchi F. Biomarkers and Lung Cancer Early Detection: State of the Art. Cancers (Basel). 2021 Aug 3;13(15):3919. doi: 10.3390/cancers13153919. PMID: 34359818; PMCID: PMC8345487.
  3. Melocchi V, Dama E, Mazzarelli F, Cuttano R, Colangelo T, Di Candia L, Lugli E, Veronesi G, Pelosi G, Ferretti GM, Taurchini M, Graziano P, Bianchi F. Aggressive early-stage lung adenocarcinoma is characterized by epithelial cell plasticity with acquirement of stem-like traits and immune evasion phenotype. Oncogene. 2021 Aug;40(31):4980-4991. doi: 10.1038/s41388-021-01909-z. Epub 2021 Jun 25. PMID: 34172935.
  4. Barisciano G, Colangelo T, Rosato V, Muccillo L, Letizia Taddei M, Ippolito L, Chiarugi P, Galgani M, Bruzzaniti S, Matarese G, Fassan M, Agostini M, Bergamo F, Pucciarelli S, Carbone A, Mazzoccoli G, Colantuoni V, Bianchi F*, Sabatino L*. miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer. Br J Cancer. 2020 Mar 5. doi: 10.1038/s41416-020-0773-2. [Epub ahead of print] PubMed PMID: 32132656. * co-last authorship
  5. Lusito E, Felice B, D'Ario G, Ogier A, Montani F, Di Fiore PP, Bianchi F. Unraveling the role of low-frequency mutated genes in breast cancer. Bioinformatics. 2018 Jun 29. doi: 10.1093/bioinformatics/bty520
  6. Monterisi S, Lo Riso P, Russo K, Bertalot G, Vecchi M, Testa G, Di Fiore PP, Bianchi F. HOXB7 overexpression in lung cancer is a hallmark of acquired stem-like phenotype. Oncogene. 2018 Jun;37(26):3575-3588. doi: 10.1038/s41388-018-0229-9.
  7. Dama E, Melocchi V, Dezi F, Pirroni S, Carletti RM, Brambilla D, Bertalot G, Casiraghi M, Maisonneuve P, Barberis M, Viale G, Vecchi M, Spaggiari L, Bianchi F*, Di Fiore PP*. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers. Clin Cancer Res. 2017 Jan 1;23(1):62-72. doi: 10.1158/1078-0432.CCR-15-3005. * co-last authorship
  8. Montani F, Bianchi F. (2016) Circulating Cancer Biomarkers: The Macro-revolution of the Micro-RNA. EBioMedicine. 2016 Feb 28;5:4-6. doi: 10.1016/j.ebiom.2016.02.038. eCollection 2016 Mar.
  9. Montani, F., Marzi, M., Dezi, F., Dama, E., Carletti, R., Bonizzi, G., Bertolotti, R., Bellomi, M., Rampinelli, C., Maisonneuve, P., Spaggiari, L., Veronesi, G., Nicassio, F., Di Fiore, PP., Bianchi, F. (2015) miR-Test: a blood test for lung cancer early detection, Journal of the National Cancer Institute 107(6), doi:10.1093/jnci/djv063
  10. Bianchi F, Nicassio F, Marzi M, Belloni E, Dall'olio V, Bernard L, Pelosi G, Maisonneuve P, Veronesi G, Di Fiore PP. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011 Aug;3(8):495-503. doi: 10.1002/emmm.201100154.
Page 5 of 587

nuovo-css

webcamlive

  twitter   facebook   youtube